Reinforcing effects of nicotinic compounds: Intravenous self- administration in drug-naive mice

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 567-573

  Rasmussen, Thøger ^a   Swedberg, Michael D B ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

( ) Epibatidine; ( ) Cytisine; ( ) Lobeline; ( ) Nicotine; (S) 3 methyl 5 (1 methyl 2pyrrolidinyl)isoaxzole; ABT 418; Cocaine; Drug naive; Mouse; Self administration

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; COCAINE; CYSTINE; EPIBATIDINE; LOBELINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT;

ANIMALS; CHOLINERGIC AGENTS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MALE; MICE; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 0032101052     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00003-3     Document Type: Article

References (35)

1. Arneric S.P., Sullivan J.P., Briggs C.A., Donelly Roberts D., Anderson D.J., Raszkiewicz J.L., Hughes M.L., Cadman E.D., Adams P., Garvey D.S., Wasicak J.T., Williams M. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoaxzole (Abt-418). A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization J. Pharmacol. Exp. Ther. 270:1994;310-318.
2. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:1994;563-569.
3. Brioni J.D., Kim D.J.B., Brodie M.S., Decker M.W., Arneric S.P. Abt-418. Discriminative stimulus properties and effect on ventral tegmental cell activity Psychopharmacology (Berlin). 119:1995;368-375.
4. Chandler C.J., Stolerman I.P. Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology (Berlin). 129:1997;257-264.
5. Clayton S.C., Reagan A.C. A total synthesis of (±)-epibatidine. Tetrahedron Lett. 34:1993;7493-7496.
6. Criswell H.E., Ridings A. Intravenous self-administration of morphine by naive mice. Pharmacol. Biochem. Behav. 18:1983;467-470.
7. Damaj M.I., Creasy K.R., Grove A.D., Rosecrans J.A., Martin B.R. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 664:1994;34-40.
8. Damaj M.I., Creasy K.R., Welch S.P., Rosecrans J.A., Aceto M.D., Martin B.R. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology (Berlin). 120:1995;483-490.
9. Decker M.W., Majchrzak M.J., Arneric S.P. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45:1993;571-576.
10. Decker M.W., Brioni J.W., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Wasicak J.T., Garvey D.S., Williams M., Arneric S.P. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoaxzole (Abt-418). A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization J. Pharmacol. Exp. Ther. 270:1994;319-328.
11. Decker M.W., Curzon P., Brioni J.D., Arneric S.P. Effects of ABT-418 a novel cholinergic ligand on place learning in septal-lesioned rats. Eur. J. Pharmacol. 261:1994;217-222.
12. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors. Lessons from behavior and implications for CNS therapeutics Life Sci. 56:1995;545-570.
13. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
14. Dworkin S.I., Mirkis S., Smith J.E. Response-dependent vs. response-independent presentation of cocaine. Differences in the lethal effects of the drug Psychopharmacology (Berlin). 117:1995;262-266.
15. Fisher M., Huangfu D., Shen T.Y., Guynet T.P.G. Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent. J. Pharmacol. Exp. Ther. 270:1994;702-707.
16. Garvey D.S., Wasicak J., Decker M.W., Brioni J.D., Sullivan J.P., Carrera G.M., Holladay M.H., Arneric S.P., Williams M. Novel isoxazoles which interact with brain cholinergic channel receptors that have intrinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. 37:1994;1055-1059.
17. Gopalakrishan, M.; Monteggia, L. M.; Anderson, D. J.; Molinari, E. J.; Piattoni-Kaplan, M.; Donelly Roberts, D.; Arneric, S. P.; Sullivan, J. P.: Stable expression, pharmacological properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. J. Pharmacol. Exp. Ther. 276:289-297, 1996.
18. Goldberg S.R., Spealman R.D., Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science. 214:1981;573-575.
19. Grahame N.J., Cunningham C.L. Genetic differences in intravenous cocaine self-administration between C57BL/6J and DBA/2J mice. Psychopharmacology (Berlin). 122:1995;281-291.
20. Khan, I. M.; Yaksh, T. L.; Taylor, P.: Epibatidine binding sites and activity in the spinal cord. Brain Res. 753:269-282, 1997.
21. Koob G.F. Drugs of abuse. Anatomy, pharmacology and function of reward pathways Trends Pharmacol. Sci. 13:1992;177-184.
22. Kuzmin A., Zvartau E., Gessa L.G., Martellotta M.C., Fratta W. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 41:1992;497-500.
23. Kuzmin A., Patkina N.A., Zvartau E. Analgesic and reinforcing effects of morphine in mice. Influence of Bay K-8644 and nimodipine. Brain Res. 652:1994;1-8.
24. Martellotta M.C., Kuzmin A., Zvartau E., Cossu G., Gessa G.L., Fratta W. Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacol. Biochem. Behav. 52:1995;271-274.
25. Reavill C., Walther B., Stolerman I.P., Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 29:1990;619-624.
26. 3H]dopamine release by nicotine in rat nucleus accumbens. J. Neurochem. 49:1987;1449-1454.
27. Sahakian B., Jones G., Levy R., Gray J., Warburton D. The effects of nicotine on attention, information processing and short-term memory in patients with dementia of the Alzheimer type. Br. J. Psychiatry. 154:1989;797-800.
28. Semenova S., Kuzmin A., Zvartau E. Strain differences in the action of morphine in mice. Pharmacol. Biochem. Behav. 50:1995;17-21.
29. Sloan J.W., Martin W.R., Bostwick M., Hook R., Wala E. The comparative binding characteristics of nicotinic ligands and their pharmacology. Pharmacol. Biochem. Behav. 30:1988;255-267.
30. Stolerman I.P. Basic mechanisms of nicotine addiction. ECNP. 2:1992;282-283.
31. Stolerman I.P., Reavill C. Primary cholinergic and indirect dopaminergic mediation of behavioral effects of nicotine. Prog. Brain Res. 79:1989;227-237.
32. Stolerman I.P., Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol. Sci. 12:1991;467-473.
33. Swedberg M.D.B., Henningfield J.E., Goldberg S.R. Nicotine dependency. Animal studies Wonnacott S., Russell M.A.H., Stolerman I.P. Nicotine psychopharmacology. 1990;39-76 Oxford University Press, Oxford.
34. Swedberg M.D.B., Rimvall K., Suzdak P.D. Lobeline and cytisine. Evidence for partial agonism in the drug discrimination procedure Soc. Neurosci. Abstr. 20:1994;1136.
35. Swedberg M.D.B. The mouse grid-shock analgesia test. Pharmacological characterization of latency to vocalization threshold as an index of antinociception J. Pharmacol. Exp. Ther. 269:1994;1021-1028.